By accounting for developability in candidate selection, drug developers have the potential to greatly minimize costly attrition and reduce development time significantly. However, this rapidly expanding area is not without its challenges, and key issues surrounding the early implementation of molecular assessments and rational engineering approaches need to be addressed.
Developability of Biopharmaceuticals has been designed to support drug developers in reducing the cost, risk and time of development. Our agenda focuses on the opportunities such as monitoring protein thermostability to ensure optimal conditions for bioprocess and exploring new high throughput screening methods to improve confidence in candidate selection.
Organizer: Hanson Wade